Home › Psoriasis › NCT03827876

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

An Open-Label Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Male or female adult ≥ 18 years of age;
* Diagnosis of chronic plaque-type
* Patient with 2-10% BSA
* Physician Global Assessment of 2 or greater
* Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks

Exclusion Criteria:

* ˂2 or \>10% BSA
* PGA \<2
* Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab \<24weeks

About the study

4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

What is being tested

• Enstilar 0.005%-0.064% Topical Foam (drug)

Sponsor: Psoriasis Treatment Center of Central New Jersey · Participants: 30 · Started: Jan 16, 2019

Contact the study team

• Jerry Bagel, MD · Phone: 6094434500
• Elise Nelson · Phone: 6094434500

Official record on ClinicalTrials.gov — NCT03827876

Locations in the U.S.

Conditions

• Psoriasis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.